Using multiple murine models of human solid carcinomas, we examined the immunomodulatory effects and anti-tumor efficacy of N-IL15/PDL1, a novel bifunctional immune-oncology agent comprising N-IL15 fused to two single chain anti-PD-L1 variable region domains. Here, CD274 is linked to neoplasm.